`Case 1:18-cv-00924—CFC-SRF Document 479-4 Filed 01/14/20 Page 1 of 2 PageID #: 33832
`
`
`
`
`
`EXHIBIT D
`
`EXHIBIT D
`
`
`
`Case 1:18-cv-00924-CFC-SRF Document 479-4 Filed 01/14/20 Page 2 of 2 PageID #: 33833
`
`From:
`Sent:
`To:
`
`Cc:
`Subject:
`
`Arora, Priya <PArora@cooley.com>
`Wednesday, January 8, 2020 6:02 PM
`SERVICE-HER-BIOSIM; WH GNE-Amgen Herceptin Service List; dsilver@mccarter.com; Joyce,
`Alexandra; Henry Huttinger; EWiener@durietangri.com
`Armon, Orion; z/Amgen-Genentech; Neal C. Belgam; Eve H. Ormerod
`Genentech v. Amgen, No. 18-cv-924 - Production of agreements
`
`EXTERNAL SENDER
`
`
`Eric,
`
`Pursuant to Genentech’s Requests for Production, we are in the process of producing relevant third‐party settlement
`and licensing, and customer agreements. Two entities, McKesson Corporation and AbbVie Inc., have requested certain
`accommodations prior to production of their agreements with Amgen:
`1. McKesson Corporation requested that Genentech agree to limit access to the agreement to outside trial counsel
`and experts disclosed under the PO.
`2. AbbVie Inc. requested that (a) only the agreement covering the US (i.e., not ex‐US) be produced, and (b) that
`Genentech agree to limit access to the agreement to outside trial counsel and experts disclosed under the PO.
`Please confirm that Genentech agrees with these requests. If there is any objection, please be ready to discuss at today’s
`meet and confer.
`
`Thanks,
`
`Priya Arora
`Cooley LLP
`3175 Hanover Street
`Palo Alto, CA 94304-1130
`+1 650 843 5384 office
`+1 650 849 7400 fax
`parora@cooley.com
`
`www.cooley.com
`
`Cooley is one of Fortune’s 100 Best Companies to Work For
`
`Cooley GO > Start and build your business
`
`
`
`
`
`This email message is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use,
`disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply email and destroy all copies of the original message.
`If you are the intended recipient, please be advised that the content of this message is subject to access, review and disclosure by the sender's Email System
`Administrator.
`
`1
`
`